Y-27632 2HCl - CAS 129830-38-2
Catalog number: B0084-457869
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Y-27632 2HCl inhibits ROCK-II while displaying little activity against PKC, cAMP-dependent protein kinase and myosin light-chain kinase (MLCK) with Ki of 26 μM, 25 μM and > 250 μM, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-457869 50 mg $228 In stock
Bulk Inquiry
Related CAS:
129830-38-2 ( Y27632 2HCl); 3146986-50-7 ( Y27632 free base)
white to off-white solid powder
(1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxamide dihydrochloride; Y27632; Y-27632; Y 27632; Y27632 HCl; Y27632 dihydrochloride
Canonical SMILES:
1.Sertoli-germ cell adherens junction dynamics in the testis are regulated by RhoB GTPase via the ROCK/LIMK signaling pathway.
Lui WY1, Lee WM, Cheng CY. Biol Reprod. 2003 Jun;68(6):2189-206. Epub 2003 Jan 22.
During spermatogenesis, cell-cell actin-based adherens junctions (AJs), such as ectoplasmic specializations (ESs), between Sertoli and germ cells undergo extensive restructuring in the seminiferous epithelium to facilitate germ cell movement across the epithelium. Although the mechanism(s) that regulates AJ dynamics in the testis is virtually unknown, Rho GTPases have been implicated in the regulation of these events in other epithelia. Studies have shown that the in vitro assembly of the Sertoli-germ cell AJs but not of the Sertoli cell tight junctions (TJs) is associated with a transient but significant induction of RhoB. Immunohistochemistry has shown that the localization of RhoB in the seminiferous epithelium is stage specific, being lowest in stages VII-VIII prior to spermiation, and displays cell-specific association during the epithelial cycle. Throughout the cycle, RhoB was localized near the site of basal and apical ESs but was restricted to the periphery of the nuclei in elongating (but not elongated) spermatids, spermatocytes, and Sertoli cells.
2.Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin.
Nishikimi T1, Tadokoro K, Wang X, Mori Y, Asakawa H, Akimoto K, Yoshihara F, Horio T, Minamino N, Matsuoka H. Eur J Pharmacol. 2002 Oct 25;453(2-3):175-81.
We investigated the direct effects of cerivastatin on hypertrophy of cultured rat neonatal myocytes induced by endothelin and the mechanism by which cerivastatin exerts its effects. Endothelin significantly increased [14C]phenylalanine ([14C]Phe) incorporation, atrial natriuretic peptide (ANP) release, ANP mRNA expression and cell size. Cerivastatin significantly reduced the increase in [14C]phenylalanine incorporation, ANP peptide release, ANP mRNA expression and cell size induced by endothelin, but pravastatin did not. Exogenous mevalonate completely prevented the inhibitory effect of cerivastatin on [14C]phenylalanine incorporation, ANP release and cell size. Cotreatment with geranylgeranyl pyrophosphate also attenuated the effect of cerivastatin on [14C]phenylalanine incorporation, but cotreatment with farnesyl pyrophosphate or squalene did not. Furthermore, both Rho inhibitor C3 exoenzyme and Rho-dependent kinase inhibitor, (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide.
3.Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells.
Adachi S1, Yasuda I, Nakashima M, Yamauchi T, Yoshioka T, Okano Y, Moriwaki H, Kozawa O. Eur J Pharmacol. 2011 Jan 10;650(1):145-50. doi: 10.1016/j.ejphar.2010.10.014. Epub 2010 Oct 16.
Although Rho-kinase is reportedly implicated in carcinogenesis and the progression of human cancers, its precise mechanism has not been fully elucidated. We recently reported that Rho-kinase negatively regulates epidermal growth factor (EGF)-stimulated cancer progression in SW480 colon cancer cells. In the present study, we investigated the effect of Rho-kinase on the migration of SW480 colon cancer cells and the mechanism underlying the involvement of Rho-kinase. Interestingly, (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 2HCl (Y27632), a specific inhibitor of Rho-kinase, dose-dependently enhanced cell migration. SW480 cells spontaneously release vascular endothelial growth factor (VEGF), however, Y27632 had little effect on its release. While Rho-kinase, which is generally phosphorylated in unstimulated cells, was clearly suppressed by Y27632, exogenous VEGF did not affect its phosphorylation. Immunofluorescence microscopy revealed that Y27632 caused a dramatic change in the localization of focal adhesion components, vinculin, phosphorylated caveolin-1 and tyrosine-phosphorylated proteins in SW480 cells.
4.M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder.
Braverman AS1, Doumanian LR, Ruggieri MR Sr. J Pharmacol Exp Ther. 2006 Feb;316(2):875-80. Epub 2005 Oct 21.
Normal rat bladder contractions are mediated by the M(3) muscarinic receptor subtype. The M(2) receptor subtype mediates contractions of the denervated, hypertrophied bladder. This study determined signal transduction mechanisms mediating contraction of the denervated rat bladder. Denervated bladder muscle strips were exposed to inhibitors of enzymes thought to be involved in signal transduction in vitro followed by a cumulative carbachol concentration-response curve. Outcome measures were the maximal contraction, the potency of carbachol, and the affinity of darifenacin for inhibition of contraction. Inhibition of phosphoinositide-specific phospholipase C (PI-PLC) with 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine (ET-18-OCH(3)) has no effect on denervated bladder contractions, whereas inhibition of phosphatidyl choline-specific phospholipase C (PC-PLC) with O-tricyclo[,6]dec-9-yl dithiocarbonate potassium salt (D609) attenuates the carbachol maximum and potency.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related ROCK Products

(CAS: 1414854-42-4)

Verosudil is a selective Rho-kinase inhibitor originated by Aerie Pharmaceuticals. In Jun 2013, Phase-II for Ocular hypertension in USA was discontinued. In Sep...

CAS 928320-12-1 AS 1892802

AS 1892802
(CAS: 928320-12-1)

AS 1892802 has been found to be an ATP-competitive ROCK inhibitor and could show analgesic activities at some extent.

(CAS: 223645-67-8)

K-115, also called as Ripasudil or Glanatec, a selective ROCK inhibitor (IC50 =31 nM), is a promising emerging antiglaucoma drug, and was thus approved by the J...

CAS 934387-35-6 ROCK-IN-1

(CAS: 934387-35-6)

A potent inhibitor of ROCK2 (IC50= 1.2 nM)

Ripasudil (K-115)
(CAS: 887375-67-9)

Ripasudil (K-115) is potent ROCK inhibitor with IC50 of 51 nM and 19 nM for ROCK1 and ROCK2, respectively, used for the treatment of glaucoma and ocular hyperte...

CAS 1342278-01-6 RKI-1447

(CAS: 1342278-01-6)

RKI-1447 is a potent Rho-associated ROCK kinase inhibitor with IC50 values of 14.5 and 6.2 nM for ROCK1 and ROCK2 respectively. It exhibits significant anti-inv...

CAS 103745-39-7 Fasudil

(CAS: 103745-39-7)

Fasudil is a potent and selective Rho-kinase (ROCK) inhibitor and vasodilator. ROCK is an enzyme that participates in vasoconstriction and vascular remodeling. ...

RKI 1447 dihydrochloride

RKI 1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC50 values of 14.5 nM and 6.2 nM, respectively. It suppresses phosphorylation of ROCK sub...

CAS 911417-87-3 KD025 (SLx-2119)

KD025 (SLx-2119)
(CAS: 911417-87-3)

KD025 is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nm, respectively. Phase 2.

CAS 1226056-71-8 Thiazovivin

(CAS: 1226056-71-8)

CAS 155558-32-0 Hydroxyfasudil Hydrochloride

Hydroxyfasudil Hydrochloride
(CAS: 155558-32-0)

Hydroxyfasudil Hydrochloride, an active metabolite of Fasudil, preferentially inhibits Rho-kinase and plays a central role in the pathogenesis of coronary arter...

Netarsudil Mesylate
(CAS: 1422144-42-0)

Netarsudil, also known as AR-11324, is a Rho-associated protein kinase inhibitor. Netarsudil is potential useful for treating glaucoma and​/or reducing intraocu...

OXA 06 dihydrochloride

OXA 06 dihydrochloride is a ROCK inhibitor with IC50 value of 10 nM. It can suppress pMYPT1 and pCofilin levels in non-small cell lung carcinoma cell lines.

CAS 864082-47-3 GSK429286A

(CAS: 864082-47-3)

GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.

CAS 850664-21-0 GSK 269962

GSK 269962
(CAS: 850664-21-0)

GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold ...

CAS 607373-46-6 SB 772077B dihydrochloride

SB 772077B dihydrochloride
(CAS: 607373-46-6)

SB 772077B dihydrochloride is a potent Rho-kinase (ROCK) inhibitor (IC50 ~ 5.6 nM at recombinant human ROCK1 and 2) exhibiting potent vasodilator activity. SB 7...

CAS 1273579-40-0 Chroman 1

Chroman 1
(CAS: 1273579-40-0)

Chroman 1, a chroman-based compound, is an effective ROCK II inhibitor which could probably influence the cell motility involved in sorts of disorders.

(CAS: 923359-38-0)

SAR-407899 is a potent, ATP-competitive ROCK inhibitor. It is equipotent against human and rat-derived Rho-kinase 2 with inhibition constant values of 36 nM and...

CAS 199433-58-4 Y-33075

(CAS: 199433-58-4)

Y-33075, also called as SNJ-1656, a well-characterized ROCK inhibitor, inhibits more potently ROCK by about 30 times than Y-27632, a common specific ROCK inhibi...

CAS 84468-24-6 C-1

(CAS: 84468-24-6)

C-1 is a protein kinase inhibitor selecitive for PKG, PKA and PKC (IC50 = 4, 8 and 12 µM, respectively) and is widely used as a ROCK inhibitor.

Chemical Structure

CAS 129830-38-2 Y-27632 2HCl

Quick Inquiry

Verification code

Featured Items